Prevention strategies in palmar-plantar erythrodysesthesia onset: The role of regional cooling

被引:47
作者
Mangili, G. [1 ]
Petrone, M. [1 ]
Gentile, C. [1 ]
De Marzi, P. [1 ]
Vigano, R. [1 ]
Rabaiotti, E. [1 ]
机构
[1] Hosp San Raffaele, IRCCS, Dipartimento Ginecol & Ostetr, I-20132 Milan, Italy
关键词
palmar-plantar erythrodysesthesia; pegylated liposomal doxorubicin; regional cooling; skin toxicity;
D O I
10.1016/j.ygyno.2007.10.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Objective. Palmar-plantar erythrodysesthesia (PPE) is a characteristic cutaneous toxicity associated with pegylated liposomal doxirubicin (PLD). Different therapies have been proposed to alleviate PPE onset. We performed a prospective study to evaluate preventive strategies to reduce PPE incidence in patients treated for gynecologic cancers. Methods. Fifty-three patients were treated from 2001 to 2006 with PLD as single agent therapy or in combination with carboplatin or paclitaxel. PLD dosages were in the range of 30-50 mg/m(2) every 21-28 days. All patients received premedication with dexamethasone and pyridoxine. Twenty-eight patients received application of ice packs on extremities during PLD infusion. Results. PPE was observed in 11 patients (20.8%). PLD administration as single agent or in combination and schedule of PLD therapy did not Fir affect PPE incidence. A significant reduction in PPE onset was observed if PLD dosage was 30-35 mg/m(2) (p=0.03) and when patients were submitted to regional cooling protocol (p=0.0097). Conclusions. The use of ice packs around wrists and ankles is a simple and well tolerated prevention strategy and its efficacy is demonstrated in this study. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:332 / 335
页数:4
相关论文
共 22 条
[1]
Bhasin S, 2005, J Assoc Physicians India, V53, P155
[2]
Oral dexamethasone attenuates Doxil®-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies [J].
Drake, RD ;
Lin, WM ;
King, M ;
Farrar, D ;
Miller, DS ;
Coleman, RL .
GYNECOLOGIC ONCOLOGY, 2004, 94 (02) :320-324
[3]
DVORAK HF, 1988, AM J PATHOL, V133, P95
[4]
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors [J].
Eng, C ;
Mauer, AM ;
Fleming, GF ;
Bertucci, D ;
Rotmensch, J ;
Jacobs, RH ;
Ratain, MJ .
ANNALS OF ONCOLOGY, 2001, 12 (12) :1743-1747
[5]
FABIAN CJ, 1990, INVEST NEW DRUG, V8, P57
[6]
A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer [J].
Gibbs, DD ;
Pyle, L ;
Allen, M ;
Vaughan, M ;
Webb, A ;
Johnston, SRD ;
Gore, ME .
BRITISH JOURNAL OF CANCER, 2002, 86 (09) :1379-1384
[7]
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan [J].
Gordon, AN ;
Fleagle, JT ;
Guthrie, D ;
Parkin, DE ;
Gore, ME ;
Lacave, AJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3312-3322
[8]
Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer [J].
Gordon, AN ;
Granai, CO ;
Rose, PG ;
Hainsworth, J ;
Lopez, A ;
Weissman, C ;
Rosales, R ;
Sharpington, T .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3093-3100
[9]
Release of doxorubicin in sweat:: first step to induce the palmarplantar erythrodysesthesia syndrome? [J].
Jacobi, U ;
Waibler, E ;
Schulze, P ;
Sehouli, J ;
Oskay-Özcelik, G ;
Schmook, T ;
Sterry, W ;
Lademann, J .
ANNALS OF ONCOLOGY, 2005, 16 (07) :1210-1211
[10]
Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers [J].
Kim, RJ ;
Peterson, G ;
Kulp, B ;
Zanotti, KM ;
Markman, M .
GYNECOLOGIC ONCOLOGY, 2005, 97 (02) :374-378